<DOC>
	<DOC>NCT00069719</DOC>
	<brief_summary>To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Adult subjects of either sex and any race with openangle glaucoma or ocular hypertension; logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>open-angle</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ocular</keyword>
	<keyword>hypertension</keyword>
	<keyword>POAG</keyword>
</DOC>